Daily Archives: October 26, 2021

Ruxolitinib is approved for chronic graft-versus-host disease

October 26th, 2021 Bone marrow transplant

October 2021: After failure of one or two lines of systemic therapy, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-versus-host disease (cGVHD) in adults and children aged 12 and up.REACH-3 (NCT031.... Read More

Tisotumab forvedotin-tftv is approved for recurrent or metastatic cervical cancer

October 26th, 2021 Cervical cancer, Chemotherapy

October 2021: The FDA has given tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor combination, rapid approval for adult patients with recurrent or metastatic cervical cancer who are progres.... Read More

Cabozantinib is approved for differentiated thyroid cancer

October 26th, 2021 Thyroid Cancer, Uncategorized

October 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) has been approved by the Food and Drug Administration for adult and paediatric patients 12 years of age and older who have locally advanced or metastatic differentiated thyroid cancer (DTC) .... Read More